Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).

Dhanasekaran, Renumathy; Gabay-Ryan, Meital; Baylot, Virginie; Lai, Ian; Mosley, Adriane; Huang, Xinqiang; Zabludoff, Sonya; Li, Jian; Kaimal, Vivek; Karmali, Priya; Felsher, Dean W

Dhanasekaran, Renumathy; Gabay-Ryan, Meital; Baylot, Virginie; Lai, Ian; Mosley, Adriane; Huang, Xinqiang; Zabludoff, Sonya; Li, Jian; Kaimal, Vivek; Karmali, Priya; Felsher, Dean W.

Afiliação

Dhanasekaran R; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Gabay-Ryan M; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Baylot V; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Lai I; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mosley A; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Huang X; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Zabludoff S; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Li J; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Kaimal V; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Karmali P; Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Felsher DW; Division of Oncology, Department Pathology, Stanford University School of Medicine, Stanford, CA, USA.